stockrow
Sunday 8 November 2026
Export PBLS’s income statement to Excel — free account
Parabilis Medicines, Inc.
PBLS
28.53
0.65
+2.33%
Follow PBLS
Alert me
Parabilis Medicines, Inc. (PBLS) P/E ratio
Parabilis Medicines, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ELVN Enliven Therapeutics, Inc. compare | n/m |
| IRON Disc Medicine, Inc. compare | n/m |
| ABCL AbCellera Biologics Inc. compare | n/m |
| IOVA Iovance Biotherapeutics, Inc. compare | n/m |
| TARS Tarsus Pharmaceuticals, Inc. compare | n/m |
| PBLS Parabilis Medicines, Inc. | n/m |
| VKTX Viking Therapeutics, Inc. compare | n/m |
| TNGX Tango Therapeutics, Inc. compare | n/m |
| ARQT Arcutis Biotherapeutics, Inc. compare | 112× |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)